Published: 2019 July 23

Vaccine Adjuvants Market

SKU : OT1707
180 pages
Report Summary
Table of Contents
List of Tables And Figures

Vaccine Adjuvants Market is segmented By Product (Adjuvant Emulsions, Pathogen Components, Particulate Adjuvants, Combination Adjuvants), By Route of Administration (Oral, Intramuscular, Intranasal, Subcutaneous, Intradermal), By Disease (Cancer and Infectious Diseases), By End User (Research and Commercial Applications), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Vaccine Adjuvants Market

Vaccine Adjuvants Market size is expected to reach USD XX billion by the end of 2029, with growth at a CAGR of ~12.5% during the forecasting period 2022-2029. Adjuvant is an ingredient used in some vaccines to enhance host immune responses in people receiving the vaccine. Vaccines are among the most effective preventative health tools against infectious diseases, cancer, allergies, and autoimmune diseases. Vaccination aims to generate a strong immune response to the administered antigen and provide long-term protection against disease. Frequently, using only the antigen is insufficient to stimulate that protective immunity. Vaccine adjuvants are compounds that enhance the specific immune responses against co-administered antigens in vaccines.

As per DataM Intelligence, Vaccine Adjuvants Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Vaccine Adjuvants Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Vaccine Adjuvants Market in the United States and Canada produces the utmost share. Whereas the European Vaccine Adjuvants Market is projected to continue its presence globally during the period of 2022- 2029.

Vaccine Adjuvants Market Scope



Market CAGR


Segments Covered

By Product, By Route of Administration, By Disease, By End-user, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To get a Free sample click here

Market Dynamics

The vaccine adjuvants market growth is driven by several factors, such as the high prevalence of infectious diseases, increased government funding for research, and growing focus on preventing diseases.

Innovations in the vaccine adjuvants to treat infectious diseases are expected to drive market growth.

On December 3, 2021, LA JOLLA, CA Scientists at the La Jolla Institute for Immunology (LJI) and the Massachusetts Institute of Technology (MIT) discovered a mechanism to boost the efficacy of COVID-19 vaccinations and any vaccine. Their current study, published in Science Immunology, suggests that a combination adjuvant dubbed a saponin/TLR agonist may improve vaccine protection. Moreover, the FDA has only approved five adjuvants for use in the United States. For instance, according to the researchers, this SMNP combo works so well because it activates so many distinct elements of the immune system. While saponin and the TLR agonist each have a purpose, combining them causes the immune system to produce more T follicular helper cells, which boost the immunological response and more interleukin-21, an antiviral cytokine.

Moreover, the combination resulted in significantly more B cells, and for B cells to make antibodies, they require the assistance of T follicular helper cells. As a result, the researchers demonstrated that SMNP was safe and effective. While further clinical research is required, SMNP could be a useful addition to the Novavax COVID-19 vaccine, which employs a more typical protein adjuvant. Thus, from the above statements, the market is expected to drive in the forecast period.


The high manufacturing cost of the drugs, Stringent regulatory policies, non-favorable reimbursement procedures in developing and underdeveloped economies, side effects of adjuvants and time-consuming approvals are the factors the market is expected to get hampered in the forecast period.

Industry Analysis

The vaccine adjuvants market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain, pricing analysis and regulatory analysis etc.

COVID-19 Impact Analysis

The introduction of numerous COVID-19 vaccines has boosted the market growth. The US Food and Drug Administration approved an emergency use authorization (EUA) in July 2022 for the Novavax COVID-19 Vaccine, adjuvanted for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. Moreover, receiving an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) and a recommendation from the Centers for Disease Control and Prevention. In that case, it will be free to states, jurisdictions, federal pharmacy partners, and federally qualified health centers (CDC). As a result, such occurrences will likely boost the market growth shortly.

Furthermore, factors promoting the growth of the vaccine adjuvants market include higher government vaccination recommendations, technical advancements, and the increased usage of combination and synthetic vaccines. On the other hand, import and export restrictions imposed by facility closures during the COVID-19 pandemic had a short-term negative influence on market growth in the preliminary phase due to supply chain disruptions and a lack of human resources.

Segment Analysis

Particulate Adjuvants segment is expected to hold the largest share in this market segment.

Particulate type adjuvants consist of alum, virosomes, and cytokines. Alum is the most commonly used and efficient adjuvant of aluminum salts. It is found in numerous vaccines, including diphtheria-tetanus-pertussis, human papillomavirus, and hepatitis vaccines. Moreover, the segment benefited due to a wide range of products and greater efficiency against diseases. Therefore, it has increased the demand for particulate-type adjuvants. Thus, from the above statements, the market accounted for the largest market share in the forecast period. 

Geographical Analysis

North America holds the largest market share of the global vaccine adjuvants market.

North America is dominating the vaccine adjuvants market in 2021. It is estimated to hold the largest market size over the forecast period (2020-2027), owing to the highly aware public, favorable government initiatives and policies, and increased research and development. The US government supports vaccine adjuvants through various government bodies, like the National Institute of Allergy and Infectious Diseases, which supports the work on new research and development, and provides funds to different countries through its parent organization National Institute of Health (NIH). NIH is collaborating with many research institutes and universities to speed up new vaccine adjuvants research. Many companies present in the region are also developing many new vaccine adjuvants. There is a presence of many major companies in the region that focus on the parent region.

Additionally, according to the National Clinical Trials (NCT) Registry, around 500 vaccine clinical trials were in development in the United States as of September 21, 2020, which is expected to have a beneficial impact on the market for these services. They can boost or activate the immune system. As a result, ongoing vaccine development clinical trials and high-quality research activities in the United States are expected to drive market growth in North America during the forecast period.

Competitive Landscape

Major key players in the vaccine adjuvants market are InvivoGen, OZ Biosciences, Sigma-Aldrich Co. LLC, SEPPIC, SPI Pharma, Agenus, Inc., Aphios Corp, VaLiant LLC, Vaxine Pty Ltd, Kineta, Inc.



InvivoGen was founded in 1997 by scientists with technical expertise and creative excellence from a longstanding history in microbiology. InvivoGen's unparalleled skill in microbial fermentation enables a wide range of biological molecules, including ultra-pure antibiotics, novel mycoplasma treatments and the largest collection of pattern recognition receptor agonists derived from a wide range of micro-organisms. In addition, the company has strong chemistry and molecular biology teams for synthesizing molecules and plasmids for research use and studies focused on gene therapy and vaccination. InvivoGen continually aims to develop tools and innovative solutions for the bioresearch community. The company's mission is to deliver the highest quality products, expand our collection of reagents, and provide dedicated technical support to customers worldwide.

­Product Portfolio:

AddaS03: AddaS03 is an oil-in-water nano-emulsion adjuvant with a formulation highly similar to the adjuvant AS03, a fundamental component of influenza vaccines. It comprises the same percentage of two biodegradable oils, squalene and DL-α-tocopherol, and the surfactant, polysorbate 80 (Tween 80), for increased stability. AddaS03 is for research use only, and not for human or veterinary use.

The global vaccine adjuvants market report would provide an access to an approx. 45+market data table, 40+figures and 180pages

Trending Topics

Vaccine Refrigerators Market

Vaccines Market

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy